[go: up one dir, main page]

AU4980697A - Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors - Google Patents

Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors

Info

Publication number
AU4980697A
AU4980697A AU49806/97A AU4980697A AU4980697A AU 4980697 A AU4980697 A AU 4980697A AU 49806/97 A AU49806/97 A AU 49806/97A AU 4980697 A AU4980697 A AU 4980697A AU 4980697 A AU4980697 A AU 4980697A
Authority
AU
Australia
Prior art keywords
inase
ortho
bicyclic heteroaryl
hydroxamic acids
tace inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU49806/97A
Other versions
AU743901B2 (en
Inventor
Jay Donald Albright
Xumei Dui
Yansong Gu
Jeremy Ian Levin
Arie Zask
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of AU4980697A publication Critical patent/AU4980697A/en
Application granted granted Critical
Publication of AU743901B2 publication Critical patent/AU743901B2/en
Assigned to WYETH HOLDINGS CORPORATION reassignment WYETH HOLDINGS CORPORATION Request to Amend Deed and Register Assignors: AMERICAN CYANAMID COMPANY
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU49806/97A 1996-10-16 1997-10-08 Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors Ceased AU743901B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73200496A 1996-10-16 1996-10-16
US08/732004 1996-10-16
PCT/US1997/018281 WO1998016514A1 (en) 1996-10-16 1997-10-08 Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Publications (2)

Publication Number Publication Date
AU4980697A true AU4980697A (en) 1998-05-11
AU743901B2 AU743901B2 (en) 2002-02-07

Family

ID=24941797

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49806/97A Ceased AU743901B2 (en) 1996-10-16 1997-10-08 Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors

Country Status (4)

Country Link
AR (1) AR009990A1 (en)
AU (1) AU743901B2 (en)
WO (1) WO1998016514A1 (en)
ZA (1) ZA979235B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU743898B2 (en) * 1996-10-16 2002-02-07 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548524B2 (en) * 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
PL339730A1 (en) * 1997-10-06 2001-01-02 American Cyanamid Co Production and application of orthosulphonamidobicycloheteroaryl hydroxamic acids as matrix-type inhibitors of metaloproteinases and tace
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
EP1147085B1 (en) 1999-01-27 2005-11-16 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AR022424A1 (en) * 1999-01-27 2002-09-04 American Cyanamid Co COMPOUNDS DERIVED FROM ACIDS ORTOSULFONAMIDO ACETYLENE AND HYDROXAMIC HYDROXAMIC HYDROARAMYL AMID OF PHOSPHINIC ACID AS INHIBITORS TACE, COMPOSITION PHARMACEUTICAL THAT UNDERSTANDS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICATION
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
AR035311A1 (en) * 1999-01-27 2004-05-12 Wyeth Corp HYDROXAMIC ACID DERIVATIVES CONTAINING ALQUINYL, AS INHIBITORS OF THE METALLOPROTEINAS OF MATRIX AND THE TACE, PHARMACEUTICAL COMPOSITION AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
SK287071B6 (en) 2000-02-21 2009-11-05 Astrazeneca Ab Piperidine- and piperazine substituted N-hydroxyformamides, pharmaceutical compositions comprising thereof, process for preparing them and their use
JP2003524008A (en) * 2000-02-21 2003-08-12 アストラゼネカ・アクチエボラーグ Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibitors
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
AR027943A1 (en) * 2000-02-25 2003-04-16 Wyeth Corp ARIL HYDROXAMIC ORTO-SULPHONAMIDE ACIDS AS MATRIX METALOPROTEINASE INHIBITORS AND PREPARATION OF THE SAME
AU2001250571A1 (en) * 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
JP4164028B2 (en) 2001-10-12 2008-10-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Alkyne matrix metalloproteinase inhibitors
CA2468761A1 (en) * 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Novel anticancer compounds
BR0213736A (en) 2001-11-01 2004-10-19 Wyeth Corp allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
BR0313460A (en) * 2002-08-13 2005-07-05 Warner Lambert Co Naphthalene derivatives as matrix metalloproteinase inhibitors
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
TW200418825A (en) 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
WO2009000832A2 (en) * 2007-06-25 2008-12-31 Boehringer Ingelheim International Gmbh Chemical compounds
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
FR2947268B1 (en) 2009-06-30 2011-08-26 Galderma Res & Dev NOVEL BENZENE-SULFONAMIDE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS
FR2947270B1 (en) 2009-06-30 2011-08-26 Galderma Res & Dev NOVEL BENZENE-SULFONAMIDE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS
US8513421B2 (en) 2010-05-19 2013-08-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Anti amphiregulin antibodies, compositions comprising same and uses thereof
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
EP3199534B1 (en) 2016-02-01 2018-09-05 Galderma Research & Development Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
DE69718038D1 (en) * 1996-10-16 2003-01-30 American Cyanamid Co PRODUCTION AND USE OF ORTHO-SULFONAMIDO-HETEROARYLHYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU743898B2 (en) * 1996-10-16 2002-02-07 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Also Published As

Publication number Publication date
AR009990A1 (en) 2000-05-17
AU743901B2 (en) 2002-02-07
ZA979235B (en) 1999-04-15
WO1998016514A1 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
AU4980697A (en) Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
AU4756097A (en) The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU4979097A (en) Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU4806097A (en) Heteroaryl succinamides and their use as metalloproteinase inhibitors
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
AU5533094A (en) Enzyme inhibitors
AU1529997A (en) Substituted histidine inhibitors of protein farnesyltransferase
PL318220A1 (en) Inhibitors of interleukin-1 converting enzyme
AU8140898A (en) Inhibitors of beta-lactamases and uses therefor
AU4640496A (en) Boronic acid and ester inhibitors of thrombin
AU3102397A (en) Metalloprotease inhibitors
AU4422096A (en) Hydroxamic acid-containing inhibitors of matrix metalloproteases
AU1616499A (en) Chemokine variants and methods of use
AU5597098A (en) Inhibitors of the enzymatic activity of psa
AU9021498A (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
EP0789309A3 (en) Compression of structured data
AU3929600A (en) Matrix metalloproteinase inhibitors and method of using same
AU3342297A (en) Matrix metalloproteinase inhibitors
AU5678796A (en) Log converter utilizing offset and method of use thereof
AU2277597A (en) New inhibitors of sh2-mediated processes
AU6905894A (en) Trichohyalin and transglutaminase-3 and methods of using same
AU4064897A (en) Mammalian ribonuclease inhibitors and use thereof
AU5702698A (en) Polyprolyl inhibitors of cyclophilin
AU1013997A (en) Amylase inhibitors
AU3717897A (en) Protease and related nucleic acid compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: WYETH HOLDINGS CORPORATION

Free format text: FORMER NAME WAS: AMERICAN CYANAMID COMPANY